enGene Q3 FY26 net loss widens 12.11% to USD 32.5 million

• enGene posted a Q3 net loss attributable to common shareholders of USD 32.5 million, or USD 0.47 a share.
• Loss widened from USD 29 million a year earlier on higher operating expenses, which rose 13.58% to USD 34 million.
• R&D spending fell 11.01% to USD 20.09 million, while G&A costs climbed 88.82% to USD 13.92 million.
• Cash, equivalents and marketable securities totaled USD 266.3 million as of July 31.
• LEGEND pivotal Cohort 1 previously showed a 54% complete response rate; updated regulatory endpoint data is planned for 4Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609080730BIZWIRE_USPR_____20260908_BW438879) on September 08, 2026, and is solely responsible for the information contained therein.